Neuroscience Applied最新文献

{"title":"Capturing the continuum in biopsychosocial research: Measurement challenges within transdiagnostic and dimensional approaches to mental disorders","authors":"Anna Schulze , Stefanie Lis","doi":"10.1016/j.nsa.2025.105508","DOIUrl":"10.1016/j.nsa.2025.105508","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105508"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers","authors":"Kate Godfrey ,&nbsp;Brandon Weiss ,&nbsp;Xinhu Zhang ,&nbsp;Meg Spriggs ,&nbsp;Joseph Peill ,&nbsp;Taylor Lyons ,&nbsp;Robin Carhart-Harris ,&nbsp;David Erritzoe","doi":"10.1016/j.nsa.2024.104092","DOIUrl":"10.1016/j.nsa.2024.104092","url":null,"abstract":"<div><div>This study investigated the effects of a single high-dose of psilocybin on personality traits in psychedelic-naïve healthy volunteers. These data originate from a larger within-subjects fixed-order design trial, where a single high dose of psilocybin (25 mg) was administered in a psychologically supportive setting and was compared against a (one-month) prior, 1 mg ‘placebo’ dose. Personality shifts were assessed by the Big Five Inventory and the Big Five Aspect Scale, while the Altered States of Consciousness questionnaire (5D-ASC) and the Psychological Insight Scale gauged the acute psychological effects of the substance. Electroencephalography provided neurophysiological insights, specifically examining alpha power and Lempel-Ziv complexity (LZc). Results indicated significant reductions in neuroticism one month after 25 mg psilocybin administration, a finding consistent with prior studies. Reductions in neuroticism were moderated by the subjective meaningfulness of the psychedelic experience, as well as by the dread of ego dissolution subscale of the 5D-ASC, suggesting a relationship between acute drug effects and enduring personality alterations. Thus, this study substantiates the role of acute psychedelic states in catalysing lasting personality transformations in a generally beneficial direction, with broader implications for therapeutic applications and understanding of personality dynamics.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 104092"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143162433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stressed! Grab a bite? Stress eating in adults with Attention-Deficit/Hyperactivity Disorder: An Ecological Momentary Assessment study","authors":"Alea Ruf ,&nbsp;Andreas B. Neubauer ,&nbsp;Elena D. Koch ,&nbsp;Ulrich Ebner-Priemer ,&nbsp;Andreas Reif ,&nbsp;Silke Matura","doi":"10.1016/j.nsa.2025.105509","DOIUrl":"10.1016/j.nsa.2025.105509","url":null,"abstract":"<div><div>Meta-analytical evidence suggests that adults with Attention-Deficit/Hyperactivity Disorder (ADHD) face a 70% higher risk for obesity. Elevated levels of stress, the lack of adequate stress coping strategies, and the tendency to overeat might make individuals with ADHD vulnerable to stress-induced eating, i.e., engaging in (over)eating when feeling stressed – a behavioural pathway through which ADHD symptomatology may contribute to obesity. Research indicates that particularly impulsivity symptoms of ADHD are associated with overeating. This study is the first to use Ecological Momentary Assessment (EMA) to assess (1) whether stress is generally associated with (over)eating in adults with ADHD and (2) whether trait and state impulsivity moderate the stress and eating relationship. Thirty-six adults with ADHD completed a 3-day EMA period. Participants reported perceived stress and state impulsivity eight times a day (signal-contingent) and recorded food intake (event-contingent). Multilevel two-part models were used to study the relationship between stress and the occurrence as well as the amount of food intake. Stress was not related to the occurrence and the amount of food intake. Trait and state impulsivity did not moderate the stress and eating relationship. This study provides preliminary evidence that adults with ADHD might not be at particular risk for stress eating. Future studies are needed to replicate these findings. Advancing our understanding of eating – a central, indispensable human behaviour – in this under-researched at-risk population is crucial given its significant public health impact due to the high disease burden and personal suffering associated with obesity and ADHD.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105509"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of psychedelics trials completed in depression, informed by European regulatory perspectives","authors":"Francisca Silva ,&nbsp;Florence Butlen-Ducuing ,&nbsp;Lorenzo Guizzaro ,&nbsp;Pavel Balabanov","doi":"10.1016/j.nsa.2025.105516","DOIUrl":"10.1016/j.nsa.2025.105516","url":null,"abstract":"<div><div>There is a growing body of clinical research on the therapeutic potential of psychedelics for the treatment of mental health disorders, notably depression. Accordingly, the new revision of the European Medicines Agency guideline on the clinical investigation of products for depression will incorporate a section covering specific regulatory recommendations for the design of studies with psychedelics. The present review investigated the methodological approaches adopted in completed controlled trials of psychedelics for depression in light of initial considerations included in the draft guideline revision. A systematic search conducted on scientific databases (Embase and Medline) and clinical trial registries (<span><span>clinicaltrials.gov</span><svg><path></path></svg></span> and WHO ICTPR) identified 8 completed trials as of February 2024. The trials tested psilocybin, LSD, Ayahuasca, and DMT, for major depressive disorder or treatment-resistant depression, and were all pahse 2 or 1/2. Patterns in pre-defined methodological variables pertaining to trial design, population, interventions, outcome measures and safety assessments were analysed and collated against considerations on unblinding and expectancy, choice of comparator, the definition of treatment frameworks, the characterisation of the subjective psychedelic experience and the specification of adverse events in relation to subjective psychedelic effects. Areas for future research, including long-term efficacy and safety and the influence of inter-individual differences, can be investigated in larger studies, necessary for marketing authorisation applications. Ultimately, balancing the intricacies of conducting trials with psychedelics with ensuring adherence to regulatory requirements can be facilitated by early dialogue with medicines regulators, and will be essential for the medical development of psychedelics to address unmet patient needs.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105516"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards collaborative data science in mental health research: The ECNP neuroimaging network accessible data repository","authors":"Adyasha Khuntia ,&nbsp;Madalina-Octavia Buciuman ,&nbsp;John Fanning ,&nbsp;Aleks Stolicyn ,&nbsp;Clara Vetter ,&nbsp;Reetta-Liina Armio ,&nbsp;Tiina From ,&nbsp;Federica Goffi ,&nbsp;Lisa Hahn ,&nbsp;Tobias Kaufmann ,&nbsp;Heikki Laurikainen ,&nbsp;Eleonora Maggioni ,&nbsp;Ignacio Martinez-Zalacain ,&nbsp;Anne Ruef ,&nbsp;Mark Sen Dong ,&nbsp;Emanuel Schwarz ,&nbsp;Letizia Squarcina ,&nbsp;Ole Andreassen ,&nbsp;Marcella Bellani ,&nbsp;Paolo Brambilla ,&nbsp;Nikolaos Koutsouleris","doi":"10.1016/j.nsa.2024.105407","DOIUrl":"10.1016/j.nsa.2024.105407","url":null,"abstract":"<div><div>The current biologically uninformed psychiatric taxonomy complicates optimal diagnosis and treatment. Neuroimaging-based machine learning methods hold promise for tackling these issues, but large-scale, representative cohorts are required for building robust and generalizable models. The European College of Neuropsychopharmacology Neuroimaging Network Accessible Data Repository (ECNP-NNADR) addresses this need by collating multi-site, multi-modal, multi-diagnosis datasets that enable collaborative research. The newly established ECNP-NNADR includes 4829 participants across 21 cohorts and 11 distinct psychiatric diagnoses, available via the Virtual Pooling and Analysis of Research data (ViPAR) software. The repository includes demographic and clinical information, including diagnosis and questionnaires evaluating psychiatric symptomatology, as well as multi-atlas grey matter volume regions of interest (ROI). To illustrate the opportunities offered by the repository, two proof-of-concept analyses were performed: (1) multivariate classification of 498 patients with schizophrenia (SZ) and 498 matched healthy control (HC) individuals, and (2) normative age prediction using 1170 HC individuals with subsequent application of this model to study abnormal brain maturational processes in patients with SZ. In the SZ classification task, we observed varying balanced accuracies, reaching a maximum of 71.13% across sites and atlases. The normative-age model demonstrated a mean absolute error (MAE) of 6.95 years [coefficient of determination (<em>R</em>^<em>2</em>) = 0.77, <em>P</em> &lt; .001] across sites and atlases. The model demonstrated robust generalization on a separate HC left-out sample achieving a MAE of 7.16 years [<em>R</em>^<em>2</em> = 0.74,<em>P</em> &lt; .001]. When applied to the SZ group, the model exhibited a MAE of 7.79 years [<em>R</em>^<em>2</em> = 0.79, <em>P</em> &lt; .001], with patients displaying accelerated brain-aging with a brain age gap (BrainAGE) of 4.49 (8.90) years. Conclusively, this novel multi-site, multi-modal, transdiagnostic data repository offers unique opportunities for systematically tackling existing challenges around the generalizability and validity of imaging-based machine learning applications for psychiatry.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105407"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143162434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Augmentative transcranial magnetic stimulation over the left orbitofrontal cortex in patients with treatment-resistant obsessive-compulsive disorder: An acute and follow-up study","authors":"Matteo Vismara ,&nbsp;Sara Torriero ,&nbsp;Kevin La Monica ,&nbsp;Beatrice Benatti ,&nbsp;Luca Larini ,&nbsp;Chiara Bucca ,&nbsp;Nicolaja Girone ,&nbsp;Monica Bosi ,&nbsp;Bernardo Dell’Osso","doi":"10.1016/j.nsa.2025.105511","DOIUrl":"10.1016/j.nsa.2025.105511","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Obsessive-compulsive disorder (OCD) is a disabling and chronic medical condition which impairs the overall functioning and the quality of life of affected individuals. At the current moment up to 60% of patients do not show a satisfactory response, and among alternative approaches for treatment-resistant OCD, repetitive transcranial magnetic stimulation (rTMS) showed promising results in terms of efficacy and tolerability. Despite this, stimulation parameters are still heterogeneous, and additional investigations are needed to support these data.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;OCD patients with characteristic of treatment resistance were included in this open-label trial. The stimulation protocol consisted of one daily session, five days a week for three weeks, for a total of 15 sessions. The left orbitofrontal cortex (OFC) was the target, stimulated at 80% of the motor threshold, with a frequency of 1 Hz, 600 pulses per session. All patients maintained fixed medication doses during the trial. Primary outcome measures comprised the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Hamilton Anxiety Rating Scale (HAM-A), the Hamilton Depression Rating Scale (HAM-D), the Sheehan Disability Scale (SDS), and the Clinical Global Impression Scale (CGI-S) scores, assessed at baseline (T0), at the end of the treatment (T1), and after a follow-up of one month (T2). We identified responders with a Y-BOCS reduction of ≥35% at T1. General linear model repeated measures were used to compare scores at psychometric scales, chi-squared test was used to compare variables between responders and non-responders.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Thirteen patients completed the psychometric assessment (males: 69.2%; females: 30.8%, mean age: 43.1 ± 10.2 years). We observed a significant reduction at the end of the treatment on the Y-BOCS (T0:23.4 ± 8.9 - T1:18.2 ± 7.2, p = 0.009), HAM-A (T0:13.8 ± 7.4-T1:8.6 ± 4, p = 0.006), HAM-D (T0:13.2 ± 5.8 - T1:9.5 ± 3.6, p = 0.014), SDS (T0:22.7 ± 6.2 - T1:18.3 ± 5.1, p = 0.008), and CGI-S scores (T0:4.8 ± 0.8 - T1:4.3 ± 0.9, p = 0.027). Among all timepoints, a trend of significance for reduction of Y-BOCS and HAM-A scores emerged (p = 0.075 and p = 0.077, respectively), while HAM-D scores were significantly reduced after one month (p = 0.047). Responders constituted 30.8% (N = 4) of the sample. Worse clinical variables were more frequently observed in non-responders compared to responders: a higher rate of psychiatric familiarity and a higher rate of lifetime suicidal ideation. The only side effect reported was mild and transient headache during stimulation (N = 1).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Our data support the efficacy and tolerability of rTMS over the left OFC on obsessive-compulsive, depressive, and anxious symptoms in treatment-resistant OCD, overall associated with a reduction of disability and functional impairment. Additionally, one third of patients showed a respo","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105511"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008–2024)","authors":"Salma Abdelmoteleb ,&nbsp;Jayant Totlani ,&nbsp;Salma Ramadan ,&nbsp;Mohamed Salem ,&nbsp;Ashley Meyer ,&nbsp;Tiffany Chang ,&nbsp;Madeline Ewing ,&nbsp;Luiza Freire ,&nbsp;Nathalie Murphy ,&nbsp;Sabrina Renteria ,&nbsp;Romana Dymkoski ,&nbsp;Omer Liran ,&nbsp;Rebecca Hedrick ,&nbsp;Itai Danovitch ,&nbsp;Robert N. Pechnick ,&nbsp;Waguih William IsHak","doi":"10.1016/j.nsa.2025.105507","DOIUrl":"10.1016/j.nsa.2025.105507","url":null,"abstract":"<div><div>This systematic review evaluates psychiatric medications for schizophrenia approved between 2008 and 2024, considering regulatory practices and approvals across multiple regions, including the United States, Europe, and Asian countries. It details the mechanism of action, indications, efficacy, dosing, and adverse effects of each medication. The methodology involved a literature search of the PubMed database for studies published from 2008 to December 31, 2024 on FDA-approved psychiatric medications and Phase 3 pipeline medications, along with additional medications approved in Europe using the keywords “schizophrenia” OR “psychosis” AND “psychopharm∗” OR “medic∗” OR “pharm∗.” An independent assessment was conducted, followed by a consensus on eligible studies for inclusion in the systematic review. From 2008 to December 31, 2024, the FDA approved 29 medications for schizophrenia including 13 long-acting injectables (LAI), in addition to that there are additional three other medications that are available in Europe but not in the United States. Additionally, 8 pipeline medications are currently in Phase-3 clinical trials including one LAI. Each medication is analyzed, and its mechanisms of action, indications, dosing, efficacy, and adverse effects are described. The 13 approved LAIs and the one LAI in the pipeline are detailed in a separate manuscript. This review highlights a significant increase in approved medications for the treatment of schizophrenia, including long-acting injectable formulations that enhance the range of existing oral therapies. Furthermore, new treatments for medication-related movement disorders have been introduced. Innovative developments in Phase-3 trials for schizophrenia medications, including new mechanisms of action and administration routes, promise to transform treatment strategies and enhance patient outcomes.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105507"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curbing the appetites and restoring the capacity for satisfaction: The impact of GLP-1 agonists on the reward circuitry","authors":"Anna Julia Krupa","doi":"10.1016/j.nsa.2025.105512","DOIUrl":"10.1016/j.nsa.2025.105512","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105512"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual reality interventions for cognitive remediation in severe mental illness","authors":"Anna Julia Krupa","doi":"10.1016/j.nsa.2025.105513","DOIUrl":"10.1016/j.nsa.2025.105513","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105513"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on: “Low-grade inflammation and serotonin 4 receptor binding in the healthy and the depressed brain”","authors":"Carmen Schiweck","doi":"10.1016/j.nsa.2025.105510","DOIUrl":"10.1016/j.nsa.2025.105510","url":null,"abstract":"","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"4 ","pages":"Article 105510"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}